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Dear Sirs,
A 56 year old man was diagnosed with B-chronic lympho-
cytic leukemia (B-CLL) in another hospital (RAI 4, BINET
C, IGHV mutated; FISH: 59% of cells trisomy 12). Treat-
ment was started with fludarabine, cyclophosphamide and
alemtuzumab. The patient received pneumocystis jiroveci
pneumonia prophylaxis and herpes prophylaxis with sul-
phamethoxazole–trimethoprim and valacyclovir. Evalua-
tion after two cycles showed evidence of response. Screening
for cytomegalovirus (CMV) and Epstein-Barr virus (EBV)
antibodies using ELISA was repeatedly negative. After
2 months the patient developed memory loss and a sensory
aphasia, and treatment including alemtuzumab was discon-
tinued. A cerebral MRI scan revealed several lesions with
some irregular and faint ring enhancement in the occipital
and frontal lobe of the left hemisphere and the frontal lobe of
the right hemisphere, with high signal intensity on T2
weighted images (Fig. 1). Treatment with amoxicillin and
cefotaxime was started and the patient was referred to our
hospital. Cerebrospinal fluid (CSF) showed 10 leucocytes
(71% lymphocytes) with an elevated total protein (1,08 g/l),
normal glucose and a monoclonal B-cell population consistent
with the B-CLL (CD5, CD19 and CD23 positive). All CSF
cultures for micro-organisms were negative. Two days after
the last negative IgG and IgM screening for EBV, PCR for
EBV in serum and CSF showed high numbers of viral copies,
respectively, 5,01E5 and 1,31E4. A biopsy of the left parieto–
occipital lesion revealed a diffuse large B-cell lymphoma
(DLBCL), positive for CD79a and CD23 and nuclear Pax-5.
MIB-1 labeling was positive in 85% of the tumor cells. The
nuclear EBV-encoded RNA stain (EBER) was strongly
positive, fitting in with the development of an EBV-associated
lymphoma. Despite high dose dexamethasone the patient
deteriorated rapidly and he died 15 days after the initial MRI
cerebrum. Autopsy was not performed.
Symptomatic CNS involvement in patients with B-CLL
is an uncommon complication and generally limited to the
meninges. Intracerebral localisations are exceedingly rare
[4]. Although development of an aggressive large-cell
lymphoma in patients with an underlying CLL occurs in
1–10% of patients, only six case reports on malignant
transformation of CLL (or Richter’s transformation)
involving the brain parenchyma have been published [2].
Alemtuzumab (Campath-1H) is an anti-CD52 human-
ized monoclonal antibody [6]. It is indicated for poor
prognosis CLL and the drug is being investigated in
combination therapies for a variety of hematological
malignancies and in multiple sclerosis. Because of its
effects on B and T lymphocytes with prolonged T-cell
deficiency, the drug is highly immunosuppressive. Indeed,
alemtuzumab is associated with a variety of opportunistic
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infections, especially CMV reactivation, herpes simplex
virus, and aspergillus infections [6]. In addition, in ale-
mtuzumab treated patients, EBV reactivation has been
described and several cases of EBV associated systemic
lymphoma have been reported [5, 7].
Our patient developed a cerebral EBV-positive immu-
nodeficiency lymphoma during alemtuzumab treatment.
The positive CD23 staining makes a transformation from
the known B-CLL a theoretical possibility, but otherwise no
clonal relationship between the CLL and NHL were
observed. Both in CSF and serum high copy numbers of
EBV were demonstrated. Moreover, the EBER staining of
the biopsy specimen was positive, identifying the relation
with EBV. Of note, in occasional cases of malignant
transformation in CLL, EBV has been identified in the
higher-grade neoplasm [3]. A retrospective study showed
16% of 25 patients with malignant transformation of CLL to
be EBV-positive, indicating a role for EBV in malignant
transformation in leukemia [1]. In our case, PCR EBV and
CMV monitoring was not performed during treatment with
alemtuzumab, and the ELISA assay for anti-EBV antibod-
ies remained negative. Only when the patient developed
severe neurological symptoms the EBV PCR was done
which revealed both in serum and CSF the EBV reactiva-
tion. PCR techniques detecting EBV have a high sensitivity
compared to the detection of antibodies with ELISA and are
not influenced by an immunocompromised state.
Because of the increasing use of alemtuzumab and the
profound and lasting immunosuppression this drug induces,
neurologists should be aware of opportunistic infections
including EBV. Regular monitoring of EBV and CMV
using PCR is indicated in patients treated with ale-
mtuzumab. If alemtuzumab treated patients develop neu-
rological signs and symptoms, opportunistic infections and
EBV induced lymphoma must be considered.
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Fig. 1 Cerebral MRI Axial MRI images a–c showing lesions in the
central and occipital regions of the left hemisphere and frontal region
of the right hemisphere with low signal intensity on T1-weighted
sequences (a), faint ring enhancement on T1-weighted sequences
after gadolinium (b) and high signal intensity with subtle low signal
intensity parts on T2 weighted sequences (c). The low signal intensity
parts on T2 weighted sequences suggests a lymphoma, but the faint
ring enhancement is not typical for this diagnosis
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